OCA
AXSM icon

Octagon Capital Advisors’s Axsome Therapeutics AXSM Stock Holding History

Octagon Capital Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,000
Closed -$1.63M – 31
2020
Q4 		$1.63M Buy
+20,000
New +$1.5M 0.56% 31

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Octagon Capital Advisors's AXSM Position: Q1 2021 in Review

Octagon Capital Advisors sold out of Axsome Therapeutics (AXSM) in Q1 2021, closing a stake of 20,000 shares — an estimated $1.63M sold.

Octagon Capital Advisors first reported a position in AXSM in Q4 2020 and held it in 1 quarter. The position peaked at $1.63M in Q4 2020. 184 funds tracked by Wall St. Rank hold AXSM as of Q1 2021.

  • Octagon Capital Advisors reported no remaining Axsome Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Octagon Capital Advisors sold 20,000 Axsome Therapeutics shares in Q1 2021, an estimated $1.63M.
  • Octagon Capital Advisors first reported a position in Axsome Therapeutics in Q4 2020 and held it in 1 quarter.
  • Octagon Capital Advisors's Axsome Therapeutics position peaked at $1.63M in Q4 2020.
  • 184 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2021.

Based on Octagon Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.